High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1447-1456

  Bensinger, W I ^a   Rowley, S D ^a   Demirer, T ^a   Lilleby, K ^a   Schiffman, K ^a   Clift, R A ^a   Appelbaum, F R ^a   Fefer, A ^a   Barnett, T ^a   Storb, R ^a   Chauncey, T ^a   Maziarz, R T ^a   Klarnet, J ^a   McSweeney, P ^a   Holmberg, L ^a   Maloney, D G ^a   Weaver, C H ^a   Buckner, C D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; THIOTEPA;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 9244263575     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1447     Document Type: Article

References (53)

1. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342, 1992
2. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/BAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444-448, 1991
3. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314-316, 1983
4. Osserman EF, Dire LB, Dire J, et al: Identical twin marrow transplantation in multiple myeloma. Acta Haematol 68:215-223, 1982
5. Fefer A, Cheever MA, Greenberg PD: Identical twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 76:1269-1273, 1986
6. Buckner CD, Fefer A, Bensinger WI, et al: Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience. Eur J Haematol 43:186-190, 1989
7. Bensinger WI, Buckner CD, Clift RA, et al: Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 10:1492-1497, 1992
8. Gahrton G, Tura S, Ljungman P, et al: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325:1267-1273, 1991
9. Reece DE, Shepherd JD, Klingemann HG, et al: Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 15:117-123, 1995
10. Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312-1322, 1995
11. Phillips GL, Shepherd JD, Barnett MJ, et al: Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 9:1880-1888, 1991
12. Dimopoulos MA, Alexanian R, Przepiorka D, et al: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324-2328, 1993
13. Fermand J-P, Levy Y, Gerota J, et al: Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 73:20-23, 1989
14. Anderson KC, Andersen J, Soiffer R, et al: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568-2576, 1993
15. Attal M, Harousseau JL, Stoppa AM, et al: High dose therapy in multiple myeloma: A prospective randomized study of the "Intergroupe Francais Du Myelome" (IFM). Blood 84:386a, 1994 (suppl 1, abstr)
16. Jagannath S, Barlogie B, Dicke K, et al: Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 76:1860-1866, 1990
17. Harousseau J-L, Attal M, Divine M, et al: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma. Blood 85:3077-3085, 1995
18. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854, 1975
19. Oken MM: Multiple myeloma. Med Clin North Am 68:757-787, 1984
20. Weaver CH, Bensinger WI, Appelbaum FR, et al: Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 14:813-819, 1994
21. Buckner CD, Appelbaum FR, Thomas ED: Bone marrow and fetal liver, in Karow AM Jr, Pegg DE (eds): Organ Preservation for Transplantation. New York, NY, Dekker, 1981, pp 355-375
22. Bast RC, Ritz J, Lipton JM, et al: Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43:1389-1394, 1983
23. Hill RS, Mazza P, Amos D, et al: Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 4:69-74, 1989
24. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
25. Bensinger W, Singer J, Appelbaum F, et al: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158-3163, 1993
26. Rowley SD: Hematopoietic stem cell processing and cryopreservation. J Clin Apher 7:132-134, 1992
27. Benyunes MC, Higuchi C, York A, et al: Immunotherapy with interleukin-2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 16:283-288, 1995
28. Fefer A, Benyunes MC, Massumoto C, et al: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41-45, 1993
29. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
30. Crawford SW: Critical care and respiratory failure, in Thomas ED, Forman SJ, Blume K (eds): Bone Marrow Transplantation. Boston, MA, Blackwell Scientific, 1994, pp 513-526
31. Shuhart MC, McDonald GB: Gastrointestinal and hepatic complications, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell Scientific, 1994, pp 454-481
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Clift R, Goldman J, Gratwohl A, Horowitz M: Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant 4:445-448, 1989
34. Cox DR: Regression models and life-tables (with discussions), J R Stat Soc B34:187-220, 1972
35. Alexanian R, Dimopoulos M, Smith T, et al: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-516, 1994
36. Tricot G, Jagannath S, Vesole D, et al: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995
37. Slattery JT, Sanders JE, Buckner CD, et al: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31-42, 1995
38. Vesole DH, Barlogie B, Jagannath S, et al: High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950-956, 1994
39. Barlogie B: Management of multiple myeloma. Blut 60:1-7, 1990
40. Lokhorst HM, Meuwissen OJAT, Bast EJEG, et al: VAD chemotherapy for refractory multiple myeloma. Br J Haematol 71:25-30, 1989
41. Gahrton G, Ljungman P, Tura S, et al: Allogeneic bone marrow transplantation in multiple myeloma, in Champlin RE, Gale RP (eds): New Strategies in Bone Marrow Transplantation. UCLA Symposia on Molecular and Cellular Biology, New Series. New York, NY, Wiley-Liss, 1991, pp 395-404
42. Harousseau JL, Milpied N, Laporte JP, et al: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833, 1992
43. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
44. 131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-1131, 1995
45. Collins C, Eary JF, Donaldson G, et al: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 34:1839-1344, 1993
46. Cunningham D, Powles R, Malpas JS, et al: A randomised trial of maintenance therapy with intron-a following high dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 12:1232, 1993 (abstr)
47. Peest D, Leo R, Bloche S, et al: Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 89:328-337, 1995
48. Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures - An effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115-123, 1994
49. Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209-1215, 1992
50. Kwak LW, Taub DD, Duffey PL, et al: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016-1020, 1995
51. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma (NHL). Blood 84:396a, 1994 (suppl I, abstr)
52. Willems P, Croockewit A, Raymakers R, et al: Selection of CD34-positive cells using immunomagnetic beads results in more than 1.5 log reduction of malignant cells in myeloma PBC autografts. ISEH 804, 1995 (abstr)
53. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390-397, 1995